FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

Published Date: 09 Sep 2026

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Read Full News

Latest News

Talc Powder Not Linked to Lung Cancer in Women

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

Saturated Fat Tied to Worse Survival After Prostate Cancer

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Medication Self-Injection Embraced by Breast Cancer Patients

Women with breast cancer show interest in self-injecting their medication.

Can 80 Gy Radiation Boost Survival in Prostate Cancer?

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

Remote CBT for Insomnia Improves Symptoms During Chemo

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Low Awareness of How to Spot Rare Breast Cancer Identified

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

Todays Updates

Nothing to Shrug About: Shoulder Reproducibility with SGRT

A pilot study suggests open-face SGRT immobilization is feasible for HN radiotherapy, with shoulder reproducibility similar to conventional masks.

Paget's Disease Mimicking Metastasis: A Diagnostic Pitfall

A case of rising PSA and widespread sclerotic bone lesions turned out to be Paget's disease, not metastasis—avoiding unnecessary ADT and bone harm.

US CDC Records More Than 3,100 Measles Cases So Far in 2026

The U.S. Centers for Disease Control and Prevention said on Friday there were 3,134 confirmed measles ⁠cases in the country so far this year, marking the highest annual...

Holistic Care Must Be Standard in Lung Disease

Experts at ERS 2026 urge clinicians to treat the whole person rather than just damaged lungs, moving from mere symptom control to focus on what matters most to each patient.

Low-Dose Sq Decitabine ± Venetoclax in Myeloid Malignancies

Across 4 VA sites, 22 veterans with AML, MDS, or CMML tolerated low-dose sq decitabine±venetoclax, showing feasibility in a hard-to-treat population.

A Novel Virtual Culinary Program for Veterans With Cancer

A single virtual cooking class helped veterans in oncology care manage appetite loss and weight change, with 9.3/10 satisfaction in this VA pilot.

Alcohol's Heart Benefit Was a Statistical Illusion

No dose of alcohol is risk-free, and none protects the heart. It's time to counsel patients on drinking less rather than where the line sits.

Todays Updates

Nothing to Shrug About: Shoulder Reproducibility with SGRT

A pilot study suggests open-face SGRT immobilization is feasible for HN radiotherapy, with shoulder reproducibility similar to conventional masks.

Paget's Disease Mimicking Metastasis: A Diagnostic Pitfall

A case of rising PSA and widespread sclerotic bone lesions turned out to be Paget's disease, not metastasis—avoiding unnecessary ADT and bone harm.

US CDC Records More Than 3,100 Measles Cases So Far in 2026

The U.S. Centers for Disease Control and Prevention said on Friday there were 3,134 confirmed measles ⁠cases in the country so far this year, marking the highest annual...

Holistic Care Must Be Standard in Lung Disease

Experts at ERS 2026 urge clinicians to treat the whole person rather than just damaged lungs, moving from mere symptom control to focus on what matters most to each patient.

Low-Dose Sq Decitabine ± Venetoclax in Myeloid Malignancies

Across 4 VA sites, 22 veterans with AML, MDS, or CMML tolerated low-dose sq decitabine±venetoclax, showing feasibility in a hard-to-treat population.

A Novel Virtual Culinary Program for Veterans With Cancer

A single virtual cooking class helped veterans in oncology care manage appetite loss and weight change, with 9.3/10 satisfaction in this VA pilot.

Alcohol's Heart Benefit Was a Statistical Illusion

No dose of alcohol is risk-free, and none protects the heart. It's time to counsel patients on drinking less rather than where the line sits.

Latest News

A study of US women finds no connection between talc powder use and lung cancer, though subgroup findings leave questions open.

The association is driven by higher rates of death from cardiovascular disease and other cancers over 13 years.

Women with breast cancer show interest in self-injecting their medication.

A modest increase in radiation dose improves progression-free survival over 10 years among men with high-risk prostate cancer — but the overall survival benefits found in a French trial are uncertain.

A new randomized trial strengthens the case for managing cancer-related insomnia with cognitive-behavioral therapy.

Researchers survey US adults to assess their knowledge of inflammatory breast cancer.

News All Time

Preschoolers With Cancer Have Poor Motor Skills

Preschool children newly diagnosed with cancer exhibit significant motor impairments, reduced mobility, and weak grip strength at diagnosis, study shows.

Breast Cancer Survivors: Who Benefits From Weight-Loss Meds?

The oral drug naltrexone-bupropion helps some breast cancer survivors lose weight.

Fixed-Duration Combo Shows Promise for Relapsed MCL

Researchers examine the efficacy of fixed-duration mosunetuzumab plus polatuzumab vedotin in patients with heavily pretreated relapsed/refractory mantle cell lymphoma.

US Cancer Trials Heavily Favor Single Drugs Over Care Issues

Industry trials focus on single drugs, while publicly funded trials often look at broader cancer care. It’s a ‘complementary’ approach, but pharma enrolls over 90% of patients.

Ruxolitinib Reduces Acute GVHD in Transplant Patients

A phase 3 trial evaluates a low-dose ruxolitinib-based regimen for graft-vs-host disease prophylaxis among patients undergoing haploidentical hematopoietic stem-cell transplantation.

HCT Survival Outcomes Improving in Relapsed Hodgkin Lymphoma

Researchers evaluate changes in post-transplantation outcomes among patients with relapsed or refractory Hodgkin lymphoma from 2010 to 2022.

How Much of a Cancer Drug Is Too Much?

In a recent KFF survey, 43% of US adults said they had skipped their medication in the past year because of cost.

Belgian Algorithm Reshapes Endometrial Cancer Care

A new Belgian algorithm may help clinicians choose adjuvant therapy more precisely in early endometrial cancer, moving beyond TNM staging alone.

NPM1-Mutated AML: Not All Treatments Are Equal

Researchers conducted a retrospective analysis of patients with newly diagnosed NPM1-mutated AML treated with high- or low-intensity regimens.

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Recommended News For You

Mutation Clearance After Transplant Linked to Better Outcomes in Myelofibrosis

Progress in Early Cancer Diagnosis; Breast Cancer in Younger Women; Diet and Cancer.

In CML Patients With New Diagnoses, STAMP Inhibitor Outperforms Imatinib and Second-Gen TKIs.

Colorectal Cancer Screening Uptake Tripled in 45-49 Age Group

How Do Younger People Fare With Stool Tests for CRC Screening?

Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

Recommended Articles For You

Obesity as a major risk factor for cancer 

Liquid Biopsy: A Game-Changer in T-Cell Lymphoma Detection and Management 

Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options  

Clinical Pharmacology of Hypoxia-Activated Anticancer Prodrugs 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

What Could This Exploratory 5-Year Survival Data in Adjuvant NSCLC Treatment Mean?

2.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

3.

Through the activation of bitter taste receptors, lidocaine has the potential to kill some cancer cells.

4.

Algorithm that predicts pancreatic cancer metastasis could help avoid unnecessary surgeries

5.

The Effect of Common Steroids on Cancer Treatments.

1.

Cardiotoxicity Beyond Anthracyclines: Redefining Risk in the Cardio-Oncology Era

2.

Precision Oncology: How Personalized Medicine is Transforming Cancer Treatment

3.

Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown

4.

Virtual Survivorship Platforms in Cancer Care: Transforming Post-Treatment Support and Outcomes

5.

Radiation in Oncology: Advances, Applications, and Accessibility

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

2.

CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

4.

From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL

5.

Exploring the Hospitalization Burden in Refractory and Relapsed ALL

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot